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In the past decade, significant progresses have taken place in the field of can-
cer immunotherapeutics, which are being developed for most human cancers. New
immunotherapeutics, such as Ipilimumab (anti-CTLA-4), have been approved for clinical
treatment; cell-based immunotherapies such as adoptive cell transfer (ACT) have either
passed the final stage of human studies (e.g., Sipuleucel-T) for the treatment of selected
neoplastic malignancies or reached the stage of phase II/III clinical trials. Immunother-
apetics has become a sophisticated field. Multimodal therapeutic regimens comprising
several functional modules (up to five in the case of ACT) have been developed to provide
focused therapeutic responses with improved efficacy and reduced side-effects. However,
a major challenge remains: the lack of effective and clinically applicable immune assess-
ment methods. Due to the complexity of antitumor immune responses within patients, it
is difficult to provide comprehensive assessment of therapeutic efficacy and mechanism.
To address this challenge, new technologies have been developed to directly profile the
cellular immune functions and the functional heterogeneity. With the goal to measure the
functional proteomics of single immune cells, these technologies are informative, sensitive,
high-throughput, and highly multiplex. They have been used to uncover new knowledge
of cellular immune functions and have been utilized for rapid, informative, and longitudinal
monitoring of immune response in clinical anti-cancer treatment. In addition, new com-
putational tools are required to integrate high-dimensional data sets generated from the
comprehensive, single cell level measurements of patient’s immune responses to guide
accurate and definitive diagnostic decision.These single cell immune function assessment
tools will likely contribute to new understanding of therapy mechanism, pre-treatment
stratification of patients, and ongoing therapeutic monitoring and assessment.
Keywords: immune function, cytokine, cancer therapy, single cell method, immune assessment, antitumor immune
response
The field of targeted cancer therapeutics and immunotherapy has
gone through significant maturation in recent years. For example,
Ipilimumab, an antibody that blocks a T-cell function-regulating
surface receptor (CTLA-4), was approved by the Food & Drug
Administration (FDA) for treatment of metastatic melanoma
(Hodi et al., 2010); Adoptive cell transfer (ACT) therapy that uti-
lizes T cells expressing transgenic T cell receptor (TCR) or chimeric
antigen receptor (CAR) has demonstrated high objective response
rate (>40%) in Phase II clinical trials (Rosenberg, 2012). The
newly approved small molecule drug, vemurafenib, or PLX 4032,
that targets BRAF oncogenic mutation (V600E), has been found to
induce T-cell mediated antitumor response (Sosman et al., 2012;
Liu et al., 2013). Through these studies and other pre-clinical
investigations, it has been increasingly recognized that immune
cells play an important, yet paradoxical, role in malignancy. Cyto-
toxic and helper T cells, natural killer cells, and antigen presenting
cells can mediate tumor destruction; whereas regulatory T cells,
indoleamine-2.3-dyoxigenase (IDO) positive dendritic cells, and
myeloid-derived suppressor cells (MDSCs) can protect malig-
nancy (Hunder et al., 2008; Kantoff et al., 2010). Therefore, a deep
understanding of the antitumor immune response and ways to
control and maintain it are crucial for designing successful cancer
therapeutics.
Immune cells execute their functions primarily through the
secretion of effector or signaling proteins, jointly called cytokines.
Hundreds of such molecules have been found and these cytokines
can mediate a myriad of functions, from direct target killing, to
self-renewal, to recruitment of other immune cell types, and to
promotion or inhibition of local inflammation. Further, due to
the variety of the pathogens it needs to target, cellular immu-
nity is inherently heterogeneous at the single cell level. Individual
immune cells can possess differential capacities in producing these
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cytokines. Therefore, a survey of immune cell function would
require the development of high-throughput, highly multiplex
single cell assays that can characterize the properties of single
immune cells in producing multiple relevant effector cytokines,
collectively called functional proteomics. An additional technical
challenge is that the assays should have the capacity to relate the
released proteins back to their cellular producers.
In this review, we will focus on recent progresses in the devel-
opment of single cell proteomics tools, with an emphasis on those
that can be used for immune diagnostics and monitoring in cancer
therapeutics. These technologies are necessarily sophisticated and
can generate large amounts of high-dimensional protein readouts.
Therefore, advanced data modeling and analysis methods that can
help interpret and visualize the readout are highly desirable. We
will review some useful methods for data processing, analysis, and
presentation in the second section. It is exciting that several tech-
nologies have been used to study primary human samples. Pilot
studies using these technologies have provided a fresh view on
the functional heterogeneity of immune cells and the dynamics
of antitumor immune response. Therefore we will review some
of the recent applications and propose potential roles of these
technologies in cancer therapy.
SINGLE CELL PROTEOMICS TECHNOLOGIES
Mass spectrometry in combination with liquid chromatography
(MS-LC) was the first tool developed for proteomics studies. It
is high-throughput and has the potential to reveal the full pro-
tein spectrum. Due to the limited amount of materials retrievable
from single cells, the application of MS-LC toward single cells is
challenging (Choudhary and Mann, 2010; Altelaar et al., 2013).
Further, MS-LC requires input of fragmented or enzyme-digested
samples and thus does not allow the recovery of viable cells
for downstream usage. There have been exciting developments
recently; however, the application of MS-LC in a clinical setting
remains to be seen (Choudhary and Mann, 2010; Altelaar et al.,
2013).
Flow cytometry, invented in the 1970s, is one of the most
advanced, versatile tools for studying single cells in immunology.
It utilizes photon detectors to measure laser-activated fluorescence
signals that are emitted from cells stained by fluorophore labeled
antibodies and uses fluidics to handle the individual cells. The
technology can be used to profile cell surface markers, phospho-
rylation during intracellular signaling and, to a limited capacity,
cytokine production. With the increasing number of fluorophores
available, currently 20 parameters can be measured; of them, up
to 5 can be cytokines (Table 1; Figure 1A) (Perfetto et al., 2004;
Betts et al., 2006). Cells can be measured at a high-throughput rate
of up to 10,000/s. The potentially complicated calibration proce-
dure to compensate the overlaps in fluorophore optical spectrum
has been standardization and automated. Multiple clinical centers
have established centralized flow cytometry facilities (Maecker and
McCoy, 2010). A version of the flow cytometry technology, called
Fluorescence Activated Cell Sorting (FACS), allows retrieving live
cells with desired surface properties. Currently, as many as four cell
populations can be purified in parallel. However, because of the
limited multiplexity (<5), the required un-physiological blockage
Table 1 | Comparison of existing single cell technologies for profiling functional proteomics.
Technology Reference Minimum
sample
(cells)
Current
multiplexity for
cytokines
Readout Throughput Multiplexity
limitation
(cytokines)
Cell
recovery
Single
cell
level
Flow cytometry
(intracellular
staining)
Appay et al. (2008),
Betts et al. (2006),
Seder et al. (2008),
Darrah et al. (2007),
Bendall et al. (2012)
105 3–5 Antibody
staining based
Fluorescence
104 cells/s <10, intracellular
space,
fluorophore
spectrum
overlapping
Yes Yes
Mass cytometry
(intracellular
staining)
Bendall et al. (2011),
Newell Evan et al.
(2012), Bodenmiller
et al. (2012), Bendall
et al. (2012)
105 9 Isotope 103 cells/s ∼10, intracellular
space, availability
of isotopes
No Yes
ELISpot Moodie et al. (2010) 105 1–3 Enzyme,
fluorescence
106–107
cells/dish
<5 No Quasi-
single cell
Single cell
barcode chip
Ma et al. (2011, 2013),
Wang et al. (2012), Lu
et al. (2013), Ma et al.
(2012a,b)
104 20 Fluorescence 103–104
cells/chip
100–1,000 No Yes
Micro-engraving Han et al. (2012),
Varadarajan et al.
(2011, 2012),
Yamanaka et al. (2013)
104–105 3 Fluorescence 103–105
cells/chip
<5 Yes Yes
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FIGURE 1 | Functional proteomics analysis by existing and emerging
technologies. (A) Detection of 5 concurrent T-cell functions and
characterization of CD8 T-cell functionality by flow cytometry. (i) Gating
scheme for identification of multifunctional CD8 T-cell responses. (ii) The
T-cell response is composed of multiple functional subpopulations. Each dot
denotes IFN-g, IL-2, and/or TNF-a positivity. (iii) The functional profile of T-cells
by pie charts. For simplicity, responses are grouped by number of functions.
(B) CD8+T cell data measured by mass cytometry. (i) One data set is
plotted on the first three principal component axes. (ii) These average
expression for each phenotypic (left plot) and functional (right plot)
parameters were normalized and plotted as a function of normalized PC2
values. (iii) Left: the combinatorial diversity of 9 T cell functions were
assessed in response to anti-CD3+anti-CD28. The heat of each block
represents the log scale frequency of cells displaying each combination of
functional capacity. Right: psuedo-colored density-dot plots of the first two
principal components are shown for cells stimulated with
anti-CD3+anti-CD28. (C) Dynamics of antitumor immune response
measured by SCBC. (i) The design of the single cell barcode chip (left) and
sample image readout of cell cytokine production (right). (ii) Gated and
background subtracted one-dimensional scatterplots of a representative
cytokines produced by single cells at different time. (iii) Cytokine secretion
florescence intensity data analyzed by PCA. (iv) Hierarchical clustering of the
19 functional cytokines produced by CD8 T cells. (v) Functional diversity
plots for antitumor CD8 T cells. (vi) Time-dependent changes of T cell
cytokine polyfunctional strength and comparison between three patients
analyzed. (Reprint permission obtained where needed.)
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of protein secretion and the non-viability of cells analyzed, this
technology is less optimal for measuring cytokine production.
One recent technical breakthrough along the direction of flow
cytometry is mass cytometry, also known as cytometry by time-
of-flight (cyTOF) (Bendall et al., 2011). The technology is based
on the detection of isotopes that do not naturally exist in biolog-
ically samples. Cells are stained by isotope-labeled antibodies and
are then “evaporated” into clouds of molecules in the machine;
thereby the isotope labeling is detected. The application of this
technology in immunology was first reported in 2011 (Bendall
et al., 2011). With proper combinatorial barcoding, the technol-
ogy has been showed to detect 30 surface markers and 9 cytokines
simultaneously (Table 1; Figure 1B) (Bodenmiller et al., 2012).
Unlike flow cytometry, whose multiplexity is limited by the over-
laps in fluorophore spectrum, mass cytometry can potentially
detect a huge number of markers simultaneously (Bendall et al.,
2012). Currently, the technology is limited by the comparatively
low-throughput rate and the low fraction of sample analyzable;
however, it is expected to improve (Bendall et al., 2012). Because
cells are“evaporated” during the assay, cells cannot be retrieved for
downstream analysis. Thanks to many shared components and
established experience available from flow cytometry, this tech-
nology grows very fast. It has been used to study the hierarchy of
hematopoietic stem cell differentiation, the natural killer cell intra-
cellular signaling and the T cell functional heterogeneity (Bendall
et al., 2011; Bodenmiller et al., 2012; Newell Evan et al., 2012), as
we will review later.
The enzyme-linked immunosorbent spot (ELISpot) or fluo-
rospot assay is a widely used quasi-single cell technique (Moodie
et al., 2010). In the assay, cells are cultured on a petri dish
that is pre-coated with cytokine-specific antibodies. Cytokines
released from individual cells are captured by surrounding anti-
bodies. Subsequently, these captured cytokines are detected by
applying secondary antibodies and fluorophore labels or through
enzymatic reaction. After the assay, the number of spots on
the petri dish, each relating to a cytokine-producing cell, can
be enumerated. ELISpot can achieve a high sensitivity (<0.1%)
and allows the detection of one to three cytokines at the same
time (Table 1). Because single cells are not separated during
the measurement, the protein level cannot be quantitated and
individual cells cannot be distinguished when cells are too close
together.
Recent developments in microfluidics have revolutionized the
traditional ELISpot assay. These microchip-based technologies
utilize arrays of highly miniaturized nano- to pico-liter volume
micro-chambers to achieve ultra-sensitive protein measurement
and the separation of single cells. Because single cells are separated
in different micro-chambers, their protein levels can be quan-
titated in parallel. About 1,000–10,000s micro-chambers can be
integrated into one microchip, to achieve high-throughput mea-
surements. The amenability of these technologies to integrate with
upstream cell purification and on-chip optical imaging further
enhances their utility. Moreover, microchips are highly portable,
low-cost, and are sample-efficient.
One version of these microchips is called the Single Cell Bar-
code Chip (SCBC) (Ma et al., 2011). It couples a microfluidics-
generated antibody microarray substrate with a microfluidics
chip containing a large array of micro-chambers. The antibody
microarray serves to detect cytokines secreted and the microchip
is designed to fit a full panel of antibodies in each micro-chamber.
During the assay, single cells are loaded into these 100-pl size
micro-chambers. Because of a 1-million fold miniaturization, the
microchip can achieve ultra-sensitivity down to 100 molecules
and only requires 10,000 cells as starting material. Currently, more
than 20 proteins can be measured simultaneously from 5 to 10
thousand micro-chambers (Table 1; Figure 1C) (Ma et al., 2011,
2012a,b, 2013; Wang et al., 2012; Lu et al., 2013). The technology
has been applied across many fields, including studying adaptive,
innate immune cells, hematopoietic stem cells, and intracellular
signaling in malignancy (Ma et al., 2011, 2012a,b, 2013; Wang
et al., 2012). In particular, this technology has been used to study
the functional heterogeneity of human T cells and clinical immune
responses in an ACT immunotherapy to metastatic melanoma (Ma
et al., 2011, 2013).
Another version of the microchips employs the micro-
engraving technique to fabricate micro-chambers (Varadarajan
et al., 2011; Yamanaka et al., 2013). In this technology, hundreds of
thousands nano-liter sized micro-chambers can be integrated into
one chip, wherein up to three types of cytokines can be measured
by antibody on the substrate (Table 1). At the same time, cells can
be stained by three colors. Immune cell – target cell interaction can
be measured by on-chip imaging and temporal cytokine produc-
tion profile can be acquired by periodically switching the antibody
substrates (Varadarajan et al., 2011; Han et al., 2012). This tech-
nology also has the capacity to retrieve viable individual cells with
desirable properties from the microchip, as has been showed in
the case of T cell cloning (Varadarajan et al., 2012). Moreover, it
has also been used to show the discordant cytokine production
dynamics of human T cells (Han et al., 2012; Yamanaka et al.,
2013).
The features of the technologies reviewed are summarized in
Table 1.
ANALYSIS METHODS
The massive, high-dimensional data generated by cytometry
and microchips has spurred the development of computational
analysis methods.
The cytokine signals are normally measured in fluorescence
intensity. To compare data acquired from different samples and
from different experiments, the background level specific for each
protein needs to be identified and subtracted. One logical way
to characterize cells is to divide them into cytokine-producing
and non-producing fractions by a gate in fluorescence level. Then,
one can focus on properties of the cytokine-producing fraction
by calculating their relative abundance as well as their cytokine
production intensity.
For flow cytometry, commercial software, such as BD Diva and
FlowJo, has been developed that can provide simple data analysis
capacity. Such software can generate one-dimensional distribution
plots and density-based two-dimensional plots and allows the user
to manually gate out desirable cell subpopulations (see example
in Figure 1Ai). However, manual gating is subjective and labori-
ous, and can generate inconsistent results when a large number of
proteins and samples are analyzed.
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An alternative approach to detect background and determine
gate is to utilize computational algorithms to fit the density dis-
tribution. Finite mixture models and their variants are commonly
used (Reynolds and Rose, 1995). Some models take into account
the skewness and kurtosis of the measured distribution and could
generate good result in many cases (Pyne et al., 2009). In parallel,
non-parametric methods have been developed to extract features
of the distribution (Walther et al., 2009; Ma et al., 2013).
The single cell functional heterogeneity can be characterized
after cytokine-producing and non-producing cells are identified.
For example, cells can be grouped into subpopulations that pro-
duce different number of cytokines and the relative abundance
of each group can be showed in a pie graph (Betts et al., 2006;
Seder et al., 2008; Ma et al., 2012a,b) (Figures 1Aii,iii). Such a
plot reflects the functional distribution. Different pie charts can
be compared for statistically significant differences (Betts et al.,
2006; Seder et al., 2008). A more thorough way to look at this
functional heterogeneity would be to further subdivide cell pop-
ulation into subpopulations producing different combinations of
cytokines. Then, the distribution can be showed as a bar group
with an accompanying matrix denoting the function combina-
tions (Figures 1Aii, Bi–iii, Ci–v) (Betts et al., 2006; Ma et al., 2011;
Newell Evan et al., 2012). This type of representation is informative
and has been used to show the profound functional heterogeneity
existed in T cell populations actively attacking tumor, comparing
to that of resting T cells (Ma et al., 2011). Furthermore, statisti-
cal indicators summarizing the functional heterogeneity can also
be defined based on this information (Figure 1Cvi) (Seder et al.,
2008; Ma et al., 2013).
Since the ultimate goal of gating is to identify biologically
significant cell subpopulations based on the type and level of
cytokines produced, computational methods have been devel-
oped that directly model the distribution of the multi-dimensional
cytokine data. Such methods utilize different versions of clus-
tering method, such as k-means clustering, hierarchical cluster-
ing, and their variants (Figure 1Civ) (Johnson and Wichern,
2007; Aghaeepour et al., 2011). The basic idea is to group the
data points by certain measure of point–point distance in the
high-dimensional space representing the cytokines measured.
One of the challenges to utilize clustering methods is to pre-
define the number of clusters exist. Most of time, such infor-
mation is not known beforehand, therefore additional indicators
and trial-and-error iterations are necessary. The gating meth-
ods and grouping methods have provided very promising results
in many cases; however, due to the often-existed complexity
and irregularity of cell population, none of these methods has
showed widespread successes (Zare et al., 2010; Aghaeepour et al.,
2011).
High-dimensional analysis is especially susceptible to multiple
data defects, an effect called curse of dimensionality (Johnson and
Wichern, 2007). First, the amount of data required to allow mean-
ingful analysis increases exponentially with the number of proteins
measured. Second, spurious correlation is more likely to happen in
high-dimensional data and the measure of distance used for clus-
tering analysis is prone to be invalid. Lastly, statistical tests need to
be redesigned when repetitively used for high-dimensional data,
as true type I error can be much larger than expected.
To address these challenges, methods have been developed to
“concentrate” the information by reducing the dimensionality.
Such an approach is also biologically sound: due to the interrelat-
ing nature of gene transcription and protein expression, protein
signals are normally correlated with each other. Therefore, only a
small number of truly independent variables or “degrees of free-
dom” exist that define the biological process. In this regard, princi-
pal component analysis (PCA) and its variants are powerful resorts
(Johnson and Wichern, 2007; Ma et al., 2012a,b, 2013; Newell Evan
et al., 2012) (Figures 1Bi,ii, Ciii). When data is meaningful and
the analysis is applied correctly, different components represent-
ing different aspects of biological information can are discovered.
At the same time the noise is reduced. Other recent development
in this direction utilized minimum spanning tree and clustering
methods to characterize and display the high-dimensional data on
a two-dimensional plane and provided a revealing illustration of
hematopoietic stem cell differentiation (Bendall et al., 2011).
CLINICAL APPLICATIONS AND FUTURE DIRECTIONS
The application of these new technologies has greatly advanced
our understanding of functional heterogeneity within immune
cells. Initial studies (Ma et al., 2011; Newell Evan et al., 2012)
on human T cells showed the existence of profound functional
heterogeneity within a population of genetically and phenotypi-
cally similar T cells and demonstrated that the level of functional
heterogeneity reflects the functional activity of T cells (Ma et al.,
2011, 2012a,b, 2013). The functional heterogeneity has also been
showed to be highly focused and the distribution of functional
subsets is significantly different from a random distribution (Ma
et al., 2011; Newell Evan et al., 2012). Thus, the functional het-
erogeneity contains valuable biological information, rather than
random biological noise.
A new insight emerges from flow cytometry and microchip
analysis is that a fraction of cells, called the polyfunctional cells,
can simultaneously secrete a large number of cytokines. They also
secreted each of these cytokines in large amounts (Betts et al.,
2006; Darrah et al., 2007; Seder et al., 2008; Ma et al., 2011, 2013).
Thus, they produced a predominant amount of cytokine in an
immune response (Ma et al., 2013). One explanation of this phe-
nomenon is that the cytokine functions are coordinated at the level
of single cells and new parameters have been defined to summa-
rize this information of polyfunctionality (Figure 1Cvi) (Darrah
et al., 2007; Seder et al., 2008; Ma et al., 2013). These parame-
ters have been found to correlate with the quality of T response
in human and animal models (Darrah et al., 2007; Seder et al.,
2008; Ma et al., 2013). For example, an index, named polyfunc-
tional strength index (pSI), is developed to summarize the joint
functional intensity from polyfunctional T cells and its distrib-
ution among cytokines (Ma et al., 2013). It is used in a recent
study that monitored the temporal changes of antitumor T cells
retrieved from metastatic melanoma patients participating in a
transgenic TCR ACT immunotherapy. By comparing the changes
in the frequency, phenotype, and polyfunctionality (summarized
by pSI) of these T cells, the study showed that only the functional
changes are highly distinguishable between patients and that the
changes correlated with the clinical outcome (Ma et al., 2013)
(Figure 1Cvi).
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These studies demonstrated the importance to understand
the functional heterogeneity of immune cells and its prelimi-
nary value in clinical diagnostics and monitoring. Because both
the cellular immunity and tumor are heterogeneous at the sin-
gle cell level, successful cancer therapeutic scheme is necessarily
personalized. Therefore, personalized diagnostic and monitor-
ing tools, such as the single cell functional analysis, are highly
desirable and can be a integrative component in the cancer
therapeutics. By understanding the functional characteristics of
their immune cells, patients can be stratified pre-treatment for
the best available treatment and their immune response can
be monitored during the therapy so that further intervention
can be applied timely. The massive information acquired are
also valuable feedbacks to guide further improvements of cancer
therapy.
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